Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2422347 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| LY2422347 | DRUG | - |
| placebo | DRUG | - |
Inclusion Criteria: * must have been diagnosed with primary insomnia * must not be significantly overweight * must be able to visit the study doctor's office once every 2 weeks for 8 weeks and willing to use a handheld electronic device as a sleep diary every day * must be able to read and speak in...
LY2422347 is an investigational small molecule being developed for sleep initiation and maintenance disorders, commonly known as insomnia. It is in Phase 2 clinical development and has not been approved by the FDA. The drug is being studied in the United States.
LY2422347 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The drug is currently in Phase 2 clinical development for sleep initiation and maintenance disorders.
LY2422347 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 clinical trial for the drug has been completed, and it is being studied for sleep initiation and maintenance disorders.
LY2422347 has one completed Phase 2 clinical trial, identified as NCT00259311. This study, titled 'Efficacy Study of LY2422347 to Treat Insomnia,' enrolled 400 participants in the United States. The trial was randomized and double-blind, though it did not use a control group.
LY2422347 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being developed by Eli Lilly and Company for the treatment of sleep initiation and maintenance disorders.